Trials / Completed
CompletedNCT00506051
ZD6474(Vandetanib) + Alimta Combo Study
A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (vandetanib) 100mg | once daily oral tablet |
| DRUG | pemetrexed | intravenous infusion |
| DRUG | ZD6474 (vandetanib) 300mg |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2006-05-01
- Completion
- 2011-10-01
- First posted
- 2007-07-25
- Last updated
- 2016-08-25
Source: ClinicalTrials.gov record NCT00506051. Inclusion in this directory is not an endorsement.